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Abstract 
Bringing a new drug to market is costly in terms of capital and time investments, and any 
development issues encountered in late stage clinical trials may often be due to in vitro - in 
vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of 
drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not 
provide the 3D structure and function of organs found in vivo, so new dynamic methods 
need to be established to aid improvement of IVIVE. This review will highlight the 
importance of model progression into dynamic systems for use within drug development, 
focussing on devices developed currently in the areas of the liver and blood-brain barrier, 
and the potential to develop models for other organ systems such as the kidney. 
…………………………………………………………………………………………………………………………………………. 
Currently, the pharmaceutical industry balances the stringent testing of drugs and 
products against soaring costs and return on investments risks. Bringing a new drug to 
market will, presently, on average cost $1.3 billion over 12 years [1] [2] with pre-clinical in 
vitro testing consuming around half of the total development time [2]. Moreover, many new 
chemical and biological entities (NCEs/NBEs) which fail late stage human testing give 
evidence that pharmacological and toxicity data from in vitro cell based assays are not 
always predictive of the clinical situation [3]. Due to these financial and time commitments, 
there is great emphasis within the industry to develop newer and more reliable in vitro and 
pre-clinical methods to accompany or replace the existing methods of NCE/NBE 
investigations. 
In vitro models, particularly cell based versions are utilised in various areas of drug 
discovery, such as target identification and validation using disease models, compound 
screening and basic cytotoxicity using static cultures, through to ADMET (absorption, 
distribution, metabolism, excretion and toxicology) studies on lead compounds. While high-
throughput cell based assays have revolutionised the efficiency and speed at which 
compounds can be screened, ADMET models ideally should be an accurate representation 
of the physiological or pathophysiological state, which may be lacking in 2D static cultures. 
Tissue engineering advances show promise in the development of models with organised 
structure and cell types similar to in vivo. However the dynamic aspect of in vitro models is 
yet to fully be addressed, although it is starting to be investigated with the use of three 
dimensional bioreactors seeded with cells. 
Within the pharmaceutical industry the absorption, distribution, metabolism and 
excretion properties of NCEs are typically investigated as part of drug metabolism and 
pharmacokinetic (DMPK) science. These DMPK properties are optimized within drug 
discovery so that an NCE has the right clinical profile, e.g. ideally a high oral bioavailability, 
an elimination half-life that enables a once daily dosing regimen, sufficient exposure at the 
target tissue and an absence of drug-drug interaction (DDI) potential [4].  In vitro 2D cell 
based models are routinely used within pharmaceutical research to investigate the DMPK 
properties of absorption (Caco-2, derived from human colon carcinoma cells), distribution 
(MDCKII-MDR1, derived from canine kidney cells) and metabolism/excretion (hepatocytes) 
for NCEs.  More recently some three dimensional models have started to be investigated to 
assess their utility in studying aspects of ADME, namely the bioartificial liver 
(distribution/metabolism/elimination), the blood brain barrier model (distribution) and the 
bioartificial kidney (excretion). This review will therefore focus on the potential of 
bioartificial devices that have been developed for therapeutic use to progress to 
pharmaceutically relevant in vitro models for use in DMPK studies. 
 
Limitations of current 2D systems 
In vitro cell based models offer several advantages over the majority of cell free 
methods as they do not require purification of the target protein, they immediately select 
against compounds that are generally cytotoxic or cannot permeate cell membranes, and 
enable measurement of functional transport activity that is more representative of the 
physiological state [5]. Using primary human cells in these assays is the ideal gold standard 
[6]; however freshly isolated cells, cell cultures or tissue fragments cannot be used to study 
effects that occur over a longer time period due to the loss of functional integrity from drug 
transporter loss and enzyme depletion after a few hours [7][8]. In addition, primary human 
cells are a scarce and precious resource. For these reasons immortalised cell lines, such as 
(transfected) MDCKII-MDR1 or Caco-2 are often utilised in favour of primary cells. Such cells 
are relatively inexpensive and easy to propagate, especially in high throughput systems, 
however due to the genetic transformation process aspects of the original cell that are 
important to ADMET studies may be lost such as transporter expression and function, and 
cell adhesion molecules [8].  
Although relatively simple and effective when using the appropriate cell type, ‘2D’ in 
vitro cell based assays encounter the traditional problems of static culture; a constantly 
changing environment due to nutrient depletion and metabolic waste accumulation. 
Strategies to improve such systems have been introduced based on mimicry of the natural 
physiological environment of the organ in question. The reestablishment of heterotypic cell-
cell and cell-extracellular matrix interactions through co-cultures and sandwich cultures of 
cells respectively have proven useful in the progression of in vitro model development for a 
number of tissue types including the liver [9] [10], brain [11] and lung [12]. These models 
show improved functionality and growth compared to their single culture counterparts, 
whilst keeping their ease of propagation and use compared to primary cell cultures, which is 
imperative when developing long term in vitro models for pharmaceutical applications. 
Perfusion systems of isolated organs or tissue fragments offer the closest ex vivo 
model of the natural physiological state, alleviating the problems encountered with static 
culture, maintaining 3D architecture and prolonging the functionality, heterogeneity, 
structural complexity and cell-cell interactions [13]. However, the shortage of organs 
available and the costs and difficulties of maintaining primary cells ex vivo make perfusion 
cultures unsuitable as a routine in vitro cell based system. 
 
Moving towards 3D systems 
The development of 3D constructs for pharmaceutical research now encompasses a 
variety of systems and devices. 3D cell culture with cell types native to a specific organ that 
are grown on natural scaffolds such as collagen, decellularised scaffolds or synthetic 
biodegradable scaffolds, present a bridge between 2D culture and the in vivo cellular 
environment. 3D devices for pharmaceutical research, with structural complexity and native 
functionality are now becoming available, however these cultures are difficult to maintain in 
vitro and still lack the vascular component of tissues. Extracellular matrix (ECM) coatings on 
scaffolds such as polymer scaffolds which release growth factors have been investigated to 
aid cell attachment, growth and partially represent the native environments which can have 
profound effects on the morphology, behaviour and functions of cells needed in drug 
discovery processes, but further work is needed to progress these cultures for use as models 
[14]. 
Bioartificial devices combine flow through systems, usually a form of simple plug 
flow bioreactor, with cells, thereby mimicking both the dynamic and cell specific aspects of 
native tissues [13]. They are being incorporated in the pharmaceutical industry due to the 
potential payoff of getting more drugs to market [15]. As will be discussed further in the 
following sections, these devices are being developed from clinically used systems, and 
whilst they offer cellular and environmental similarities, most systems currently lack the 
complex architecture and microenvironments seen in 3D constructs. 
 
Status of bioreactors in the development of in vitro models 
Bioreactors are utilised in a range of applications, from being used in the production 
of biopharmaceuticals to applications in tissue engineering such as cell expansion, 
generation of 3D tissue constructs and direct organ support devices [16] (see Table 1).  
Unlike 2D static culture, bioreactors provide a controllable environment in terms of pH, 
temperature, nutrient supply and shear stress for any cells or cellular constructs 
incorporated into them. However key limitations in 3D culture such as mass transfer of 
oxygen and nutrients to cells still apply. For example, cardiac muscle tissue contains a high 
density of cells and has a high oxygen demand which in vivo is supplied by a dense network 
of capillaries through the tissue. To gain a better understanding of the native environment 
of cardiac tissue and its influence on the synchronously contracting cardiac constructs, a 
bioreactor-based model has been developed [17]. Incorporated into this device are rodent 
cardiomyocytes and fibroblasts grown on scaffolds with a parallel array of perfused 
channels to mimic the capillary network. Blood was mimicked by supplemented media and 
the model used to assess a number of parameters  such as the impact of perfusion rates of 
oxygen on viable cell density to the define the conditions needed to culture cardiac 
constructs with clinically relevant thickness [18]. 
Hollow fibre and perfusion systems in particular are widely used in the generation of 
in vitro models. In addition to allowing users to investigate the impact of environmental 
conditions on cells, they can also be used to model pharmacological interactions of drugs 
with cells in infectious states [19] or model disease states [20]. 
Progression from these systems has generated multi-compartmental bioreactors 
that mimic the physiological environment more closely. As well as being used clinically [21], 
they are being utilised as in vitro models, like the scaling down of a 3D perfusion multi-
compartment hollow fibre liver bioreactor for use in in vitro pharmacological studies [22]. 
This bioreactor consists of three interwoven sets of hollow fibre, two for counter current 
medium perfusion and one for gas supply (Fig 1). Primary human liver cells (both 
parenchymal and non-parenchymal) are co-cultured in the extra capillary space (ECS), and 
have been shown to exhibit prolonged CYP enzyme activity when maintained for over 3 
weeks, enabling long term pharmacological studies to be carried out. Hollow fibre 
bioreactor based models are also being developed for the blood- brain barrier (BBB) and 
kidney. It is important to critically assess the individual features of established systems so 
that optimised models for pharmaceutical research can be generated, and this will be the 
focus of the remainder of the review. 
  
 
 
 
 
 
 
 
 
 
  
 
Perspectives from established systems used within pharmaceutical research 
Bioartificial Liver (BAL) devices 
The liver is the main excretory organ within the body, but as well as eliminating 
waste products through the bile, it carries out a variety of highly specialised functions; 
oxidative detoxification, intermediate metabolism and supply of nutrients, modulation of 
immune and hormonal systems and protein and macromolecule synthesis [6]. Disruption in 
these functions due to liver disorders such as acute or chronic liver failure can lead to a 
possible 90% mortality rate if essential hepatic functions are not restored during the critical 
phase of liver failure [23]. Therefore, there is great emphasis on the development of reliable 
in vitro models to assess drug interactions and pharmacological responses to prevent drug 
induced acute liver toxicity, and to accurately model liver disease states for the 
development of NCEs targeting disease induced liver failure. 
Bioartificial liver (BAL) devices have gone through many iterations whilst being 
developed as an extracorporeal device for the treatment of liver failure [24]. Early flat plate 
and monolayer bioreactors exhibited uniform cell distributions and microenvironments, but 
presented complex scale up issues and a low surface area to volume ratio [25] [26].  
Perfused beds/scaffolds promote 3D architecture of seeded cells, which when considering 
the complex architecture of the liver, is an immense advantage. The cells showed improved 
metabolic and synthetic function compared to cells cultured in a spinner flask [27], however, 
exposure to shear forces and non-uniform perfusion of medium require an improved 
bioreactor design.  Conventional hollow fibre cartridges offer increased surface area for 
attachment and immunoisolation of cells when seeded in the ECS [28]. Cells are also 
protected from shear as medium flows through the fibres. However non-uniform cell 
distribution along the fibres is a common problem, and although being beneficial in terms of 
support and improved cell growth and performance if adapted to the specific cell type [29], 
membranes can present a physical barrier against the transport of nutrients and 
metabolites. As mentioned previously, development from standard hollow fibre bioreactors 
to multi-compartmental devices such as that in Fig 1 has been a natural progression 
considering the native architecture of the liver and has been utilised for both clinical and 
pharmacological applications [22]. 
 
Cell Sources 
Hepatocytes are the primary choice for use in BAL systems as they are recognized to 
be the closest cellular model to the liver [30] [31], and carry out most of the in vivo 
metabolic processes including the synthesis and excretion of albumin, metabolism of amino 
acids, urea production and the processing and elimination of drugs and toxins. Phase I and 
phase II drug metabolising enzymes are crucial in the processing of drugs within the liver, so 
preservation of these enzymes within a model is essential to reproduce cellular 
environments in vivo. 
Cell lines have frequently been utilised for in vitro studies due to prolonged cell 
survival and ease of maintenance compared to primary hepatocytes. Popular liver derived 
cell lines such as the HepG2/C3A cell line derived from hepatomas have been used in 
pharmacological studies, recently being utilised in microfluidic bioreactors to examine the 
sensitivity of the models in response to various xenotoxins  [32] [33]. However, compared to 
primary hepatocytes, functionality is often lost or altered in these cell lines [6]. For instance, 
phase I enzymes were expressed at significantly lower levels in HepG2 cells relative to 
primary human hepatocytes [34]. Therefore, primary cells would be the ideal for 
incorporation into a pharmacologically relevant in vitro model. However, recent work has 
demonstrated the successful incorporation of a HepaRG human hepatoma cell line into a 3D 
BAL device, in which metabolic and  transporter functionalities of the cells are preserved 
from a mere few hours in suspension to at least one week in the 3D device, thereby 
enabling performance of longer-term in vitro pharmacological studies[35] [36] [37]. 
Primary porcine hepatocytes have been widely incorporated into BAL devices [38] 
[39] as they are readily available, are able to maintain differentiated metabolic functions 
under certain culture conditions, provide a high yield of cells [40] and have a similar 
metabolic profile to human hepatocytes [41]. The environmental triggers that sustain 
differentiated hepatic function in vitro however, have not been fully characterised 
[42].Utilising porcine cells addresses the problem of finding a sustainable source of 
hepatocytes; however, it would be important to obtain cells derived from a human source 
to establish a representative model of the natural physiological environment for in vitro 
pharmacological studies in both normal and diseased states. 
Primary human adult hepatocytes are considered to be the gold standard for 
biocompatibility and functionality within BAL systems [6] [43], but exhibit a rapid, time-
dependent, general loss of function in vitro [7]; including reduced cytochrome P450 and 
other biotransformation enzyme activities [44] and the down regulation of liver enriched 
transcription factors such as CCAAT/enhancer binding protein alpha [43]. However, the use 
of complex chemically defined media has allowed hepatocytes to go through a number of 
cycles in culture as well as stabilize hepatocyte morphology, survival, and liver-specific 
functions [45] [38] [46] [43]. Co-culture with non-parenchymal cells has also shown to 
preserve liver specific functions including initiating physiological reorganisation of cells and 
the distribution of canalicular transporters similar to the pattern found in vivo [22]. The 
mechanisms behind these changes are not fully understood, but highly conserved signalling 
pathways are thought to be involved [9]. 
There is also limited availability of adult human hepatocytes due to their acquisition 
from liver biopsies, which has presented problems with utilising this source in clinically used 
devices as the number of cells needed for seeding a BAL for the treatment of hepatic failure 
is quite large, approximately 2 x 1010 [26] [47]. However the number of cells needed for 
bioreactor based models are approx. 3 x 108 per device [22], which could be attained with 
minimal culture in vitro. 
 
Device designs and functionality 
Within the native liver, hepatocytes are ordered in a 3D lobular network of 
hexagonal constructs, surrounding a central blood vessel. Individual cells possess polarity 
between the apical domain interfacing with bile canaliculi and a basal domain interfacing 
with the sinusoid, helping localise specific functions. During culture, hepatocytes flatten and 
spread upon attachment, whether grown on a flat surface or a scaffold. Although cell-cell 
junctions can be formed, the cytoskeleton is largely disrupted, and leads to loss of cell 
polarity, and ultimately liver specific functions [6]. 
Nonetheless, C3A cells and primary porcine cells have been utilised within hollow 
fibre bioreactors (HFBs) in clinically tested devices. The Extracorporeal Liver Assist Device 
(ELAD) consists of a dual pump dialysis system connected to one or more hollow fibre 
cartridges seeded with C3A cells in the ECS. Blood is ultrafiltered and pumped through fibres, 
with plasma flowing through the ECS. This direct interaction allows cellular processes to 
occur before the ultrafiltrate is filtered by a dual membrane to remove cells and cellular 
debris and returned back into the blood stream [48]. 
The liver has an oxygen rich environment, fed by the hepatic arteries and portal vein. 
Unsurprisingly, an improvement in functionality of C3A cells in HFBs was noted when red 
blood cells were added in culture medium [49], highlighting that an adequate oxygen supply 
is a prerequisite for the maintenance of hepatocytes in vitro. Considering this, the Excorp 
medical bioartificial liver support system (BLSS) incorporates an oxygenator and heat 
exchanger along with a blood pump and HFB seeded with primary porcine hepatocytes in 
the ECS [50]. Whole blood flows through the fibre, protecting the cells from host 
immunological responses [39]. 
Another BAL, the modular extracorporeal liver support system (MELS) has attempted 
to take into account the biliary system of the liver which excretes conjugated bilirubin and 
metabolites. Hollow fibre bundles, seeded with human hepatocytes from discarded donor 
livers are incorporated alongside a detoxification module for removing albumin bound 
toxins. This provides an inlet of plasma and contact with hepatocytes in the ECS, an outlet of 
plasma, and hydrophobic membrane bundles for gas exchange inside the bioreactor [51]. 
The structure of the seeded bioreactor module is an early iteration of the multi-
compartmental bioreactor being developed for in vitro pharmacological studies by Gerlach 
et al (described above and in Fig 1). 
These systems, although showing positive biochemical changes in patients and 
maintaining patients through to transplantation, show no significant effect on survival, and 
therefore can be assumed to be unsuitable replicates of the environment in vivo. Aspects 
such as co-culture of non-parenchymal and parenchymal cells, efficient oxygenation of cells 
and the presence of a biliary system for the removal of toxic protein bound substances and 
other metabolites should be taken forward in the generation of both efficient in vitro 
models, as has been demonstrated in the multi-compartmental liver bioreactor (Fig 1), and 
clinically relevant medical devices. 
 
Use of BALs in DMPK studies 
Bioreactor-based models are currently being integrated into the DMPK process, 
initially assessing the functionality of cells within the systems relative to drug transporter 
and metabolic enzyme expression and function. When investigating the metabolism of 
diclofenac, freshly isolated human hepatocytes were found to produce 90% less 
hydroxydiclofenac, the hydroxylated product of diclofenac generated directly by the 
cytochrome P450 enzyme CYP2C9, after a 3-day culture in 2D conditions compared to a high 
level of metabolites from human hepatocytes in the multi-compartmental bioreactor 
described above [35] [22]. The major intermediary diclofenac metabolite, diclofenac acyl 
glucuronide (produced from the glucuronidation of diclofenac by UDP-
glucuronosyltransferase (UGT) enzymes before hydroxylation by the P450 enzyme CYP2C8), 
was found to be absent in human hepatocyte suspensions, but present in the hepatocyte 
seeded bioreactor, possibly due to the bioreactor system mimicking the in vivo environment 
and allowing the efflux of metabolites away from the cells, thereby avoiding further 
metabolism. Overall, the relative levels of the metabolites found in the suspensions versus 
the 3D cultures were similar; however, all human in vivo metabolites were detected in the 
bioreactor culture, whereas one major in vivo metabolite was not present in the hepatocyte 
suspension. In addition the biotransformation capacity of the hepatocytes within the 
bioreactor was retained for at least a week, providing a good model for metabolite 
investigations from slowly metabolised drugs [35]. The activity of CYP3A4 was demonstrated 
in the 3D bioreactor system by monitoring the metabolism of atorvastatin acid (ATA) to its 
2- and 4- hyroxylated metabolites [36], and for HepaRG cells in the 3D system by monitoring 
midazolam, which indicated that CYP3A4 activity was retained for up to 2 weeks [48]. This 
retention of CYP3A4 activity is longer than that currently available in other in vitro models. 
Transporter expression is also a key aspect in the functionality of hepatocytes for 
DMPK screens. Within the bioreactor, immunohistochemical staining of multidrug resistance 
associated protein (MRP2) and multidrug resistance protein (MDR1), both bile canicular 
efflux transporters, showed expression, localisation and distribution similar to native liver 
tissue for at least 2 weeks within the bioreactor [37] [22]. The basolateral uptake 
transporter organic anion transporting polypeptide 1B1 (OATP1B1) expression has also been 
investigated on hepatocytes within the 3D system being preserved for 9 days, Functional 
activity of OATP1B1 was demonstrated by the transport of substrates estradiol- 17β-D- 
glucuronide (E17βG) and ATA in the presence and absence of the inhibitor estrone-3-
sulphate (E3S), and was retained for 7 days compared to the decrease of functional activity 
of OATP1B1/1B3 in plated primary human hepatocytes after just 2 hours [52] [36]. When 
assessing drug-drug interactions, OATP1B1 is a vital hepatic transporter to evaluate, as it is 
inhibited by many commonly used drugs, and is responsible for the targeted uptake of the 
widely prescribed statins to their site of action [53]. This has been demonstrated by similar 
increases in the elimination half-life of ATA in the presence and absence of OATP1B1 
inhibitors, with a 2.7 fold increase in the presence of rifampin [54], and a 1.7 fold increase in 
the presence of E3S within the bioreactor model. The difference in these values had been 
attributed to experimental setup and potencies of the two inhibitors, and it is also been 
noted that the major limitation of this model lies in the variable quality of isolated human 
hepatocytes from different donors [36]. However, these initial studies into the functionality 
of drug transporters and metabolic enzymes clearly establish the potential of this model for 
use throughout the DMPK process. 
For both the medical devices and in vitro models highlighted above there are 
currently no standardised criteria to define the efficiency and efficacy of these systems. 
Furthermore, any criteria applicable to a device will be partly dependent on the type of 
bioreactor used, i.e. hollow fibre systems require tight monolayers of cells on the extra 
luminal side of the fibre membrane. However, cellular metabolic functions and enzymatic 
and transporter retention is paramount in all bioartificial liver systems. From the clinically 
relevant devices mentioned above, there is little focus on the performance of cells, and 
factors used to determine the efficiency of the systems before being used in clinical studies 
are not clearly stated. Devices that have been utilised for pharmaceutical (DMPK) research 
go further in defining the criteria used to assess the models, such as monitoring metabolic 
activity via albumin synthesis, lactate dehydrogenase or aspartate aminotransferase, and 
drug metabolising enzymatic activity via administration of drugs with cytochrome P450-
dependent metabolism, as well as drug transporter functionality and visualisation by 
inhibitor transport assays and staining [22] [35] [36]  [37] [52] [53] [54]. With the 
progression of these systems, both medical and in vitro models, standardised criteria 
defining the performance relative to native conditions of the above mentioned factors 
should be produced. 
 
 Blood brain barrier models 
The BBB is one of the most important lines of defence against infections in the brain, 
acting as a physical and metabolic barrier between the central nervous system (CNS) and 
systemic circulation and maintaining homeostasis within the brain. The capillary structure is 
distinct from those found in peripheral tissues with the presence of tight junction proteins 
between endothelial cells, the restriction of transcellular movement of molecules and 
contact of endothelial cells with astrocytes to provide support  [55], protection from 
hypoxia and aglycemia and to separate capillaries from neurons [56]. 
The decreased paracellular permeability of the BBB, while possessing multidrug 
transporters such as P-glycoprotein, prohibits the transport of large drug molecules into the 
CNS, presenting the need for a reliable in vitro model for ADME studies. Existing models 
have not been characterised as well as liver devices, partly due to their lack of clinical 
relevance regarding the generation of an extracorporeal device, but also due to the 
complexity of cell alignments and functionality within the model. However, like the BAL 
devices, HFBs have been developed and utilised as ‘dynamic’ models of the BBB [57]. 
Model designs 
Unlike liver models and bioartificial devices, there is no one cell type that can be 
incorporated to mimic the BBB. Most models reported in the literature use two cell types; 
endothelial cells and glial cells (astrocytes). Early models simply used mono/co-cultures of 
endothelial cells (EC) alone or with glial cells cultured on transwell plates. This approach is 
attractive due to its simplicity, however, primary ECs lose their BBB properties in vitro due 
to the absence of stimuli that are normally present in vivo [57]. Furthermore, specific 
transporters such as P-gp are down-regulated in the absence of astrocyte-derived soluble 
factors leading to abnormal permeability across the monolayer [58]. This de-differentiating 
process may also be accelerated by non-physiological conditions such as the presence of 
serum on both sides of the polarised EC monolayer instead of only on the luminal surface in 
vivo. Co-culture models incorporating glial cells mimic the in vivo situation more closely, 
demonstrated by the increased expression of brain endothelial marker enzymes, 
transporters, and an increased trans-endothelial electrical resistance (TEER) across the 
barrier indicative of a ‘tight’ monolayer. This model is effective for studies around the 
function of the BBB and processes and interactions between the ECs and the glia [57]. 
However, for a replicative model of the BBB, factors such as shear stress, which is vital to 
promote growth inhibition and differentiation of ECs and allows trafficking of metabolic 
fuels to the brain, should be incorporated into animal based models before ideally 
progressing into human based models to allow direct extrapolation of data from studies, 
and functional and physiological mimicry of the human BBB in vivo [59]. 
Dynamic (flow based) models incorporate HFBs with coated fibres seeded with ECs 
(intraluminally) and glial cells (extraluminally). In an early model developed by Stanness et al 
[60] ECs and corresponding glial cells from human, rat and bovine sources were cultured 
successfully in a HFB coated with ProNectin (Table 2) [60]. Morphology and growth patterns 
were consistent with all cell types, however it was noted that when differing types of ECs 
and glial cells were cultured, such as human umbilical cord ECs with C6 cell line glial cells, 
BBB properties were not developed. Poor EC growth in the absence of glial cells within the 
hollow fibres was observed via low transendothelial resistances and studies assessing the 
transport of morphine demonstrated permeability ratios to be similar to in vivo, but 
absolute values to be lower. This was thought to be due to the differences in flow rate 
patterns in the devices and from in situ. The results supported the use of HFBs in BBB 
models; however, as bovine aortic endothelial cells + C6 seeded cartridges were used for 
drug transport studies, utilising human brain ECs in the HFBs would be a natural progression. 
Neuhaus et al [61] utilised a commercially available bioreactor from the same 
manufacturer as Stanness et al, and seeded immortalised porcine brain microvascular 
endothelial cells (PBMEC/C1-2) intraluminally with the glial cell line C6 cells in the extra 
capillary space. Medium was pumped through the system applying shear stresses of 2.7-3.9 
dyne m-2, mimicking conditions in brain capillaries. Results of cell growth and transport of 
benzodiazepenes were compared between the transwell and flow based models. They 
showed that PBMEC/C1-2 cells seeded on the transwell inserts started detaching after 5 
days prohibiting the use of transwell systems in long term experiments, whereas growth and 
morphology of the ECs in the HFB was affected due to exposure to flow, prolonging the 
survival of the cells within the device. Permeability coefficients of benzodiazepenes were 
also shown to be lower in the HFB model, presumably due to tighter monolayers and 
improved barrier functions within the device [61]. 
The BBB is a very active site in terms of transport, expressing multiple drug 
transporters to restrict compounds with high affinity for efflux transporters and low 
transcellular membrane permeability into the CNS. However, due to its complexity, there 
are very few established in vitro models, and CNS targeted compound analysis relies heavily 
on in vivo and in silico assessments. P-gp (MDR1) is a predominant efflux transporter in the 
BBB, capable of limiting the penetration of a wide range of substrates into the brain. For this 
reason, MDCK-MDR1 cellular bidirectional transport assays are currently used in DMPK 
screening to assess both CNS penetrating and restricted compounds, as appropriate 
depending upon target profile [4]. Differences in transporter expression and passive 
permeability have been shown in 2D static co-culture models (described above). However, 
investigations have also highlighted interspecies variability, with a 2-fold higher permeability 
in a rat EC and glial model than in the human counterpart. The limitations of the current 
transwell model utilising transfected cell lines are its static nature and lack of availability of 
human cells. However, this system could be improved by using rat ECs and glial cells, to 
better represent the in vivo environment than is currently available with transfected cell 
lines alone, in order to account for the difference in permeability [62]. Due to the nature of 
individual transporter testing in current 2D cultures, 3D models exhibiting BBB 
characteristics could also be utilised for drug-drug interaction studies as the 3D liver models 
are starting to investigate. 
Overall, the outcomes of these models are promising for the use of HFBs in 
pharmacological applications. However, the human brain is more complex than its rodent 
counterpart, and although many drug transporter proteins are expressed in rodent ECs [57], 
primary human ECs and glial cells would ideally be incorporated into an optimised device. 
This may be difficult to generate for large scale studies as healthy human glial and ECs are 
scarcely available, so one possible source would be the differentiation of stem cells into 
these cell types. However, extensive work in stem cell differentiation and characterisation 
from embryonic and induced pluripotent stem cells is needed, and is not a viable source for 
models at present. Recreating aspects of the microenvironment of the CNS in terms of ECM 
proteins surrounding glial cells may also improve performance of the cells within the device. 
 
 
 
 
 
 
 
Progressions in bioartificial kidney (BAK) devices as an in vitro model 
The need for an optimised model from existing clinical devices 
The kidneys are primarily responsible for the excretion of waste products such as 
urea and ammonia from the body through the urine. They also provide a variety of 
significant secondary functions through homeostatic, endocrine, immune and metabolic 
processes. 
Chronic kidney disease (CKD) is a growing problem within the UK, with around 1.8 
million people diagnosed in England alone. This is putting a growing burden on the NHS, 
costing over £1.4 billion a year which is largely due to renal replacement therapy e.g. dialysis, 
which showed a 29% increase in usage from 2002-2008, and complications such as heart 
disease and stroke [63]. This highlights the need for early diagnosis of the disease, more 
efficient and cost effective renal replacement therapies, more effective drug treatments and 
consequently, an optimised kidney model for pharmacological studies. 
Existing bioartificial kidney (BAK) devices have been developed primarily as a renal 
replacement therapy. They incorporate both mechanical and biological processes, pumping 
haemofiltered blood through a renal assist device (RAD). Coined by Humes et al this device 
contains renal cells seeded in the lumen of hollow fibres of a standard haemofiltration 
cartridge [64], contrary to BALs which utilise cells within the ECS. Unlike dialysis, which just 
provides intermittent filtration, in vitro studies of the BAK device show differentiated active 
transport of essential nutrients such as glucose, amino acids and sodium bicarbonate, 
sufficient metabolic activity and important endocrine processes [65]. Although the current 
bioartificial systems have been utilised for clinical use, there is scope as with the systems 
mentioned previously to use them as a foundation for many other applications. 
There have been two main groups focusing on the development of a BAK device for 
clinical use. Humes et al developed a device to treat patients with acute renal failure and 
multiple organ failure with a degree of success, while Saito et al focused on the prevention 
and treatment of long term complications in patients on maintenance dialysis [66]. Both 
devices however utilise the same bioartificial component, hollow fibre modules seeded with 
proximal tubule cells (PTCs), and pass ultrafiltered blood through the module before 
administering back into the patient (Fig 2). Humes et al [67] utilised commercially available 
haemofiltration cartridges, with polysulfone (PSF) based fibres seeded with human PTCs 
(hPTCs). Although confluent monolayers of cells were observed within the fibres [65], Saito 
et al, concurring with Zink et al [68] has commented on the lack of biocompatibility of PSF 
and PSF-based membranes for generating a confluent monolayer of cells [66]. The clinical 
trial undertaken with the BAK device from Humes’s group has also been critically assessed, 
noting the lack of documentation on expected effect size, the incompletion of treatment of 
patients assigned to CVVH + RAD treatment and the lack of statistical significance of the 
primary results with comparisons performed as an as-treated rather than an as-randomised 
intention to treat sample [69]. 
 
Cell Sources 
To create an efficient, reliable model of the kidney in situ, a BAK device must 
incorporate a cell type that can carry out a number of native functions, and so research has 
been drawn to renal PTCs. These cells perform a variety of renal specific functions including 
reabsorption, metabolic and transport functions, the secretion of uremic toxins and 
xenobiotics and performing immunomodulatory functions [70]. Renal PTCs also possess a 
range of transporters such as organic anion and organic cation transporters for basolateral 
drug uptake and ABC transporters present on the apical surface for luminal excretion into 
urine. Many of the transporters are polyspecific i.e. accept compounds of different sizes and 
molecular structures, and have overlapping substrate specificities [71]. 
Primary hPTCs are required for clinical BAK devices but the sheer number of cells 
needed (approximately 109 renal cells per device) is a major obstacle to their widespread 
use, driving the search for alternative cell sources. Human PTCs have also been used as a 
well-characterized in vitro model of the kidney in drug transport studies, owing to the 
classification of specific carrier proteins on the plasma membrane by substrate specificity 
and functional assessment, and the prediction of drug-drug interactions based on 
competitive inhibition for transport [72].  Two transporters, organic anion transporter (OAT) 
1 and OAT3 are thought to be the major OATs responsible for the basolateral uptake of 
various organic ions from the blood in vivo; OAT3 action demonstrated by the mediation of 
rosuvastatin uptake in vitro in the presence and absence of probenecid, a uricosuric drug 
[73]. Probenecid has also been shown to be a potent inhibitor of OAT2 and OAT4, where 
PGF2α uptake by OAT2, and estrone-3-sulfate uptake by apically located OAT4, was inhibited 
in the presence of probenecid. The main uptake transporter of organic cations in hPTCs is 
thought to be organic cation transporter 2 (OCT2) located on the basolateral membrane. 
Functionality has been demonstrated in hPTCs by the decrease in uptake of ASP+ in the 
presence and absence of the inhibitor quinine [74]. Although drug-drug interactions for 
organic cations have been observed in other cell sources such as LLC-PK1 cells, little data on 
the drug interactions for OCT2 has been documented [75]. Similar to liver, P-gp is 
documented to transport a wide range of xenobiotics, in particular anti-cancer agents such 
as methotrexate and cisplatin [76] in hPTCs. However, in hydrophilic statin efflux it has been 
found to have a minor role compared to the MRP2 and BCRP efflux transporters [73]. 
Differences between effects of drugs in vivo and in vitro has also been highlighted by the 
inhibitory effects of KW-3902 and betamipron on OAT4 in vitro, which showed no significant 
inhibitory effects on OAT4 in vivo [77]. 
The expression of both phase I (11 CYP enzymes and 3 glutathione S-transferases 
(GSTs)) and phase II (3 UGT and variable expressions of 3 sulfotransferases) drug 
metabolising enzymes have also been found to be retained within primary hPTC cultures. 
Furthermore, when grown in a confluent monolayer, which is necessary in current BAK 
devices, the expression of these enzymes were generally maintained at a measurable level, 
albeit lower than in the native tissue [78]. Selective drug transporter loss upon primary cell 
culture has been identified to be a consequence of dedifferentiation.  However, recent 
novel human tubular kidney cell cultures grown on permeable filter supports have been 
shown to express a wide range of drug transporters due to the co-culture of proximal and 
distal tubular cells [71]. This finding is concurrent with the increased function from co-
culture of hepatocytes and non-parenchymal cells in BAL devices. Collectively, these results 
indicate that primary cultures of hPTCs can metabolize drugs, provide good models for drug 
interaction studies and benefit the clinical setting when incorporated into BAK devices. 
Although hPTCs do not always represent in vivo functionality, these results could be 
improved by the incorporation into a dynamic bioreactor, providing a more accurate model 
of hPTCs in situ. 
Using immortalized cell lines eliminates the problem of needing vast numbers of 
cells for studies. Methods such as cloning, derivation from cancerous cells and viral 
transfection can all produce genetically stable, but functionally altered cells. Human cells are 
relatively difficult to immortalize and do not express differentiated features in vitro [65][79]. 
The established cell line HK-2, generated from the infection of human PTCs with an 
immortalizing construct from the human papilloma virus, and the more recently developed 
human kidney proximal tubular cell line (HKC) from exposure of renal epithelial cells to 
Adeno 12:SV40 hybrid virus, therefore do not provide an adequate replacement for primary 
cells for use in clinical BAK devices [79]. Other established animal derived cell lines such as 
LLC-RK1, LLC-PK1 and MDCKII have also provided adequate models for research, but 
interpretation to the human situation is often difficult due to species differences, especially 
with regard to transporters and enzymes. Drug transport with human renal cell lines has not 
been widely researched, possibly due to the substantial loss of differentiated function from 
the immortalization of human cells, and primary hPTCs or transfected animal cell lines such 
as MDCKII-MDR1 are more frequently used. This highlights the challenge of generating a 
physiologically complex, well characterised and validated in vitro cellular model which can 
replace current FDA recommended cell transport test systems such as P-gp transfected 
MDCK or LLC-PK1 cells [80]. 
Porcine PTCs are widely used in kidney research due to their reliability, anatomical 
and physiological similarity to hPTCs. In preclinical studies, porcine PTCs in a BAK device 
were shown to tolerate the uremic environment while providing metabolic, reabsorptive 
and endocrinologic activity in uremic dogs [81], allowing research to further investigate the 
benefits of BAKs, and progress to hPTC utilization for clinical trials. There are few studies 
into differences in drug interactions and metabolism between porcine and human PTCs to 
date, although drug transporter expression on primary porcine PTCs and cell lines are 
comparative to native human kidney cells (Table 3). Both primary and porcine cell lines are 
readily available and are an established model for drug toxicity, however, an optimized 
model for drug toxicity would require human PTCs instead of the readily available 
established porcine model. 
Due to their multipotency and self-renewal capabilities, embryonic stem cells may 
provide a reliable source of PTCs for use in BAK devices when exposed to the right 
environmental cues [64]. Studies into human ESCs differentiating into renal cells have not 
been widely undertaken, however preliminary studies have shown integration of 
undifferentiated and mesoderm- derived ESCs into the stroma and developing nephrons 
[82]. They have also been shown to express a wide range of early renal markers, and exhibit 
up-regulation of kidney precursor markers such as EYA1, LIM1, CD24 [83]. The generation of 
the different types of renal cells from human ESCs however still needs to be thoroughly 
investigated [82]. Due to the sparse studies and various obstacles, drug metabolism and 
transport by human ESC-derived renal cells has not been documented, but will be essential 
in any progression of stem cell utilisation towards potential in vitro cell models used in 
pharmaceutical research. 
 
Device designs 
As mentioned above, the existing devices used for clinical applications utilise 
haemofiltration cartridges seeded with hPTCs. However for an in vitro model, device design 
could be optimised. For example the number of cells needed could be greatly decreased due 
to the reduction of the size of the cartridge. Hollow fibre cartridges could also be greatly 
optimised, as commercially available modules have varying degrees of biocompatibility. 
Tailoring fibre materials to different cell types and sources have been thought to improve 
cell performance, and for primary hPTCs it is thought that some of the membrane 
properties needed include a hydrophilic, negatively charged adhesive surface [29]. When a 
variety of commercially used membranes, such as regenerated cellulose (RC), PSF/PVP and 
polyethersulfone (PES)/PVP coated with ECM, were tested with primary hPTCs, performance 
of the cells was not improved, indicating that these materials are not suitable for use in BAK 
devices. The differing properties between cell sources is further highlighted by reports that 
PSF membranes coated with ECM are able to maintain both primary porcine [84] and 
LLC-PK1 cell monolayers for 3 weeks after confluency [85]. 
Coating commercially available fibres with tailored ECM is preferable to tailoring 
membrane materials due to the ease of assembly and cost effectiveness. Various single and 
double coatings have been tested, including collagen IV and laminin blends with a variety of 
growth factors [70]. Single coatings demonstrated little improvement on hPTC performance 
within the fibre however double coatings of DOPA (3,4-Dihydroxy-Lphenylalanine) and 
collagen IV on haemocompatible membranes have revealed functional epithelia formed by 
hPTCs in a HFB [68]. Bioreactor configuration should also be taken into consideration to 
achieve both native mimicry and produce an optimal environment for the cells to proliferate. 
Previous bioartificial devices utilising hollow fibre cartridges have encountered problems 
with the non-uniform distribution of cells and the lack of transport of gases and nutrients 
[86], so including an oxygenator or aerated medium would need to be considered. 
Additionally, in order to mimic the kidney the device would need to include a tubule (hollow 
fibre) and capillary/blood (extracapillary space) section with shear rates according to native 
conditions. These would be higher in the ECS (typically 10 dyn/cm² on endothelial cells in 
vivo) than in the fibre (typically 1 dyn/cm² on PTCs in vivo) [87]. This may lead to movement 
of molecules through the membrane if the monolayer of cells is not tight, and affect cell 
performance due to varying pressures. However, from previous devices used clincally, no 
loss of membrane integrity has been reported when using different flow rates in the tubule 
and ECS [67]. 
Emerging in vitro models have also adhered to the established hollow fibre 
structure. The Wyss Institute at Harvard University have introduced ‘organs on a chip’. 
These microfluidic devices, in this case ‘kidney on a chip’ utilise hPTCs seeded within a 
microfluidic channel apposed to a polyester membrane. The channel is immersed in medium, 
and a shear stress of 0.2 dyn/cm3 is applied through the channel (Fig 3). Cytoskeletal 
proteins, tight junction proteins, ion transporters and specific drug transporters (e.g. OCT2) 
have shown improved results in a fluidic model compared to a static version, and the 
nephrotoxic compounds such as cisplatin have shown the ability of the microsystem to 
recapitulate the in vivo toxicity of the drugs. Overall, the system presents a substantial 
answer to the need of a reliable 3D in vitro model [88]. However, functional characterisation 
of the drug transporters within the device that are acknowledged to be of clinical 
importance to drug disposition by the FDA, namely P-gp, BCRP, OCT2, OAT1 and OAT3, 
should be undertaken to establish an ideal model system [89]. 
 
 
 
 
 
Conclusion and future perspectives 
Bioreactors have been utilised in many different areas of industry and research, and 
for the progression of in vitro models of 2D cultures and suspensions to 3D constructs 
mimicking the natural physiological state in situ, they have proven to be crucial. The 
generation of bioartificial devices provide both the structural and biological aspects, which 
have been exploited for clinical and research purposes. The most established bioartificial 
system, the bioartificial liver, is a prime example of the development of a bioreactor 
designed initially for therapeutic use, being utilised as an in vitro model. From simple 
perfused bed and hollow fibre bioreactors, focus on the native liver structure and cellular 
functionality within the device has prompted multi-fibre bundle designs. 
In addition to bioreactor design, development of the BBB models have highlighted 
the importance of cell sources, especially with co-culture of different cell types, within a 
fluidic system opposed to a static culture. It is understood that primary human cells are the 
gold standard for an in vitro model, however, due to the difficulty of acquisition, BBB 
models have had to utilise other primary sources. Embryonic stem cells could be a possible 
answer to the dilemma of availability for the future; however, more research is needed to 
investigate the difference in properties between primitive and mature human CNS and 
endothelial cells before incorporation into a device for DMPK investigation. 
Bioartificial kidney devices have followed the progression of BAL systems. From 
development for clinical use as a renal replacement therapy for acute and chronic renal 
conditions, they are now starting to reveal their potential as in vitro models (Fig 4). Primary 
human cells have been utilised within the system, and are fairly easy to acquire and 
maintain, especially with the reduced cell number requirement in a model. Co-culture with 
distal tubule cells however has not been fully investigated within a BAK device, and 
functional characterisation of drug transporters crucial for ADME studies have not been 
undertaken in the existing microfluidic system. 
To date, there are no universal criteria laid out to aid the development of an 
acceptable/suitable bioreactor. However, it is widely accepted that in vivo micro 
environmental aspects such as cell viability, cell-cell interactions, cell-matrix interactions, 
tissue architecture and cell oxygenation are vital to give an accurate representation of the 
physiological state, and consequently the effects of new chemical entities [3]. It is therefore 
important to bear in mind those factors which are specific to the desired tissue when 
developing in vitro models for use in pharmaceutical research. Furthermore, it is noticeable 
that little or no measurements are currently taken from these bioreactor-based devices to 
help control or monitor cell health or functionality during use.  We thus anticipate that, with 
the continuing advances being made in sensor technology,  the next generation of devices 
will incorporate  these to either improve device function or longevity. 
Bioartificial systems have started to show great promise in the generation of in vitro 
models for various organs and disease states. Observations from existing systems are the 
importance of mimicry of both structure and environments in situ in the bioreactor, the 
choice of cell and source to model the functions of the organ and essential factors for 
maintaining cellular function such as oxygen availability and nutrient and metabolite 
delivery. With these factors in mind, successful models utilising bioreactors can be achieved 
in the near future and will hopefully provide a better means to predict clinical outcome from 
in vitro data. 
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Figure legends: 
Figure 1: (a) Smallest capillary unit with 2 medium capillaries that are independently 
perfused (red and blue) and one gas capillary (yellow); cells are cultured within the extra-
capillary space (cell compartment). (b) The bioreactor consists of 3 interwoven capillary 
bundles each made of multiple hollow fibre capillaries for counter-current medium 
perfusion (red and blue) and gas supply (yellow), which allows decentralised nutrient and 
O2/ CO2 exchange with low gradients. (c) Down-scaling of the clinical- scale bioreactor 
prototype with a cell compartment volume of 800ml was realised by reducing the length 
and number of capillary layers in 2 axes of 3D space within the bioreactor, resulting in a 
laboratory- scale bioreactor with a cell compartment volume of 8 ml and a further down-
scaled model with a cell compartment volume of 2ml. Figure and caption taken from 
Zeilinger et al [22]   
 
 
Figure 2: Schematic diagram of (a) bioartificial kidney device used for the treatment of acute 
renal failure developed by Humes et al (b) bioartificial kidney device developed as a renal 
replacement therapy for chronic renal failure by Saito et al. Based on device layouts from 
[67], [66]. The devices have similar components and configurations; however the device by 
Saito et al incorporates a continuous haemofilter for continuous treatment.  
 
Figure 3: Schematic of human kidney proximal tubule-on-a-chip in the form of multi-layer 
microfluidic device by integrating a polydimethylsiloxane (PDMS) microfluidic channel, a 
porous membrane, and a PDMS reservoir. Human primary proximal tubule cells were 
cultured on the device. Modified with permission from Jin Jang et al [88].  
 
Figure 4: Key aspects from the progression of bioreactor based in vitro models and future 
developments [22] [61] [68]. 
 
Bioreactor type Pros Cons Uses Ref 
   
Spinner flasks/ Stir tank 
 
 
 
 
 
 
 
 
 
 
Pros: 
 
- Induces 
movement of oxygen and 
nutrient within culture 
medium 
- Easy to scale up 
 
Cons: 
 
- Perception that shear 
stress can have 
damaging effects on 
cells 
- Poor mass transfer 
when applying to static 
scaffolds 
 
Uses: 
 
Growth of cartilage 
constructs 
 
[19] 
 
Hollow fibre 
 
 
 
 
 
 
 
 
 
Pros: 
 
- Efficient surface area for 
attachment 
- Potential for 
immunoisolation 
- Perception that cells are 
protected from shear 
 
Cons: 
 
- Non-uniform cell 
distribution 
- Fibre membrane can 
act as a physical 
transport barrier 
 
Uses: 
 
Generation of a 
bioartificial liver 
support system 
 
[20] 
 
Perfused beds/ Scaffolds 
 
 
 
 
 
 
 
Pros: 
 
- Uniform cell distribution 
- Good distribution of 
nutrients and gas transfer 
- Stable microenvironment 
 
Cons: 
 
- Complex scale-up 
- Cells exposed to shear 
stresses 
- Low surface area to 
volume ratio 
 
Uses: 
 
Cartilage construct 
engineering from 
chondrocyte seeded 
scaffolds 
 
 
[21] 
Table 1: Bioreactor designs and uses in tissue engineering applications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flat plate + monolayer 
 
 
 
 
 
 
 
Pros: 
 
- Promotes 3D structure 
formation 
- Reduced physical 
transport barriers 
- Easy to scale up 
 
Cons: 
 
- Non-uniform 
distribution of cells 
- Cells exposed to shear 
stresses 
- Nutrient and oxygen 
transfer issues 
 
Uses: 
 
Early bioartificial liver 
system studies 
 
[22] 
Table 2: Performance of various cell types within the HFB in the generation of an in vitro 
BBB model 
Endothelial Cell (EC) Glial Cell Days prolonged in culture Ref 
 
Rat brain microvascular 
endothelial cells (RBMEC) 
 
 
Rat brain astrocytes (RBA) 
 
30 
 
[63] 
Human brain endothelial 
cells 
 
Human foetal astrocytes Not reported [63] 
Bovine aortic endothelial 
cells  
C6 glial cell line 30 [63] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Drug transporter orthologues present on MDCKII and LLC-PK1 cell lines and 
primary porcine PTCs1 
Transporter Family 
 
Gene 
Product 
Location MDCK 
II 
LLC-
PK1 
Primary 
Porcine Cells 
Ref 
Organic anion transporters OAT1 
(SLC22A6) 
Basolateral X X ~ [85] [86] [87] 
[88] 
 OAT2 
(SLC22A7) 
Basolateral    [85] [86]  
 OAT3 
(SLC22A8) 
Basolateral X X √ [85] [86] [87] 
[88] 
 OATP1A2 
(SLCO1A2) 
Apical X X +/- [88] [89] 
ATP binding cassette (ABC) transporters MRP1 
(ABCC1) 
 
MRP5 
(ABCC5) 
Basolateral √ √ √ [85] [86] [87] 
[88] [89] 
 
[85] [86] [87]  
 MRP2 
(ABCC2) 
MRP4 
(ABCC4) 
Apical √ √ √ [85] [86] [87] 
[88] [89] 
[85] [86] [87]  
 MRP3 
(ABCC3) 
Basolateral √   [85] [86]  
 MRP6 
(ABCC6) 
Basolateral √   [85] [86]  
 MDR1 
(ABCB1) 
Apical √ √ √ [85] [86] [87] 
[89]  
 BCRP 
(ABCG2) 
Apical √ √ X [85]  
Organic cation transporters OCT1 
(SLC22A1) 
Basolateral X X ~ [85] [86] [87]  
 1 Human drug transporter orthologues present on the cell lines and primary cells. Blank fields indicate no 
presence of transporters on the cells. Abbreviations: √, present; X, absent; +/-, only detectable after 35 cycles 
of PCR; ~, only present in freshly isolated samples. 
 
 OCT2 
(SLC22A2) 
Basolateral    [85] [86] [87]  
 OCT3 
(SLC22A3) 
Basolateral    [85] [86] [87]  
Carnitine/organic cation transporters OCTN1 
(SLC22A4) 
Apical    [85] [86] [87]  
 OCTN2 
(SLC22A5) 
Apical    [85] [86] [87]  
Organic anion transporting polypeptides OATP4C1 
(SLCO4C1) 
Basolateral    [87] [89]  
Peptide transporters PEPT1 
(SLC5A1) 
Apical X √ √ [85] [86] [87] 
[88] 
 PEPT2 
(SLC5A2) 
Apical X X √ [85] [86] [87]  
Multidrug and toxic compound extrusion 
transporters 
MATE1 
(SLC47A1) 
Apical    [87]  
 MATE2-K 
(SLC47A2) 
Apical    [87]  
 Fig 1. 
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